Perspectives in cancer chemoprevention

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 4, 1997, Pages 945-954

  Stoner, Gary D ^a   Morse, Mark A ^a   Kelloff, Gary J ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti initiation; Antiprogression; Antipromotion; Cancer; Chemoprevention; Mechanisms

Indexed keywords

AMINE; BLOCKING AGENT; CARCINOGEN; NITRITE; NITROSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DIET; HUMAN; NONHUMAN; PH; PRIORITY JOURNAL; TIME; TUMOR PROMOTION;

ANIMALIA;

EID: 0030807381     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s4945     Document Type: Conference Paper

References (164)

1. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 14:1737-1746 (1993).
2. Kelloff GJ, Boone CW, Malone WF, Steele V. Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. In: Cancer Chemoprevention (Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds). Boca Raton, FL:CRC Press, 1992;41-56.
3. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 3:85-98 (1994).
4. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54:2015s-2024s (1994).
5. Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS. Chemoprevention. CA Cancer J Clin 45:31-49 (1995).
6. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Doody LA. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem Suppl 19:1-9 (1994).
7. Boone CW, Kelloff GJ. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia. J Cell Biochem Suppl 19:10-22 (1994).
8. De Flora S, Izzoti A, Bennicelli C. Mechanisms of antimutagenesis and anticarcinogenesis: role in primary prevention. Basic Life Sci 61:1-16 (1993).
9. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 5(Suppl):5023s-5044s (1991).
10. ACS. Cancer Facts and Figures, 1995. Atlanta, GA:American Cancer Society, 1995; 1-3.
11. Wattenberg LW. Chemoprevention of cancer. Cancer Res 45:1-8 (1985).
12. Mirvish, SS. Ascorbic acid inhibition of N-nitroso compound formation in chemical, food and biological systems. In: Inhibition of Tumor Induction and Development (Zedeck MS, Lipkin M, eds). New York:Plenum, 1981:101-126.
13. Hartman PE, Shankel DM. Antimutagens and anticarcinogens: a survey of putative interceptor molecules. Environ Mol Mutagen 15:145-182 (1990).
14. Kuenzig W, Chau J, Norkus E, Holowaschenko H, Newmark H, Mergens W, Conney AH. Caffeic acid and ferulic acid as blockers of nitrosamine formation. Carcinogenesis 5:309-314 (1984).
15. Shenoy NR, Choughuley ASU. Inhibitory effect of diet related sulfhydryl compounds on the formation of carcinogenic nitrosamines. Cancer Lett 65:227-232 (1992).
16. Wakabayashi K, Nagao M, Sugimura T. Heterocyclic amines, lipophilic ascorbic acid, and thioproline: ubiquitous carcinogens and practical anticarcinogenic substances. In: Cancer Chemoprevention (Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds). Boca Raton, FL:CRC Press, 1992;311-325.
17. Fiala ES, Bobotas G, Kulakis C, Wattenberg LW, Weisburger JH. The effects of disulfiram and related compounds on the in vivo metabolism of the colon carcinogen 1,2-dimethylhydrazine. Biochem Pharmacol 26:1763-1768 (1977).
18. Wattenberg LW. Inhibition of carcinogenic effects of polycyclic hydrocarbons by benzyl isothiocyanate and related compounds. J Natl Cancer Inst 58:395-398 (1977).
19. Wattenberg LW. Inhibitory effects of benzyl isothiocyanate administered shortly before diethylnitrosamine or benzo[a]pyrene on pulmonary arid forestomach neoplasia in A/J mice. Carcinogenesis 8:1971-1973 (1987).
20. Morse MA, Wang C-X, Stoner GD, Mandal S, Conran PB, Amin SG, Hecht SS, Chung F-L. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA adduct formation and tumorigenicity in the lung of F344 rats by dietary phenethyl isothiocyanate. Cancer Res 49:549-553 (1989).
21. 6-methylguanine formation, and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res 49:2894-2897 (1989).
22. Morse MA, Eklind KI, Amin SG, Hecht SS, Chung F-L. Effects of alkyl chain length on the inhibition of NNK-induced lung neoplasia in A/J mice by arylalkyl isothiocyanates. Carcinogenesis 10:1757-1759 (1989).
23. Morse MA, Eklind KI, Hecht SS, Jordan KG, Choi C-I, Desai DH, Amin SG, Chung F-L. Structure-activity relationships for inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) lung tumorigenesis by arylalkyl isothiocyanates in A/J mice. Cancer Res 51:1846-1850 (1991).
24. Stoner GD, Morrissey DT, Heur Y-H, Daniel EM, Galati AJ, Wagner SW. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylmethylamine Carcinogenesis in the rat esophagus. Cancer Res 51:2063-2068 (1991).
25. Morse MA, Eklind KI, Amin SG, Chung F-L. Effect of frequency of isothiocyanate administration on inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary adenoma formation in A/J mice. Cancer Lett 62:77-81 (1992).
26. Morse MA, Zu H, Galati AJ, Schmidt CJ, Stoner GD. Dose-related inhibition by dietary phenethyl isothiocyanate of esophageal tumorigenesis and DNA methylation induced by N-nitrosomethylbenzylamine in rats. Cancer Lett 72:103-110 (1993).
27. Wilkinson JT, Morse MA, Kresty LA, Stoner GD. Effect of alkyl chain length on inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis and DNA methylation by isothiocyanates. Carcinogenesis 16:1011-1015 (1995).
28. Stoner GD, Siglin JC, Morse MA, Desai DH, Amin SG, Kresty LA, Toburen AL, Heffner EM, Francis DJ. Enhancement of esophageal Carcinogenesis in male F344 rats by dietary phenylhexyl isothiocyanate. Carcinogenesis 16:2473-2476 (1995).
29. Wargovich MJ. Diallyl sulfide, a flavor component of garlic (Allium sativum), inhibits dimethylhydrazine-induced colon cancer. Carcinogenesis 8:487-489 (1987).
30. Sparnins VL, Barany G, Wattenberg LW. Effects of organosulfur compounds from garlic and onions on benzo[a]pyrene-induced neoplasia and glutathione S-transferase activity in the mouse. Carcinogenesis 9:131-134 (1988).
31. Wargovich MJ, Woods C, Eng VWS, Stephens LC, Gray K. Chemoprevention of N-nitrosomethylbenzylamine-induced esophageal cancer in rats by the naturally-occurring thioether, diallyl sulfide. Cancer Res 48:6872-6875 (1988).
32. 1. Nutr Cancer 15:87-95 (1991).
33. Dixit R, Teel RW, Daniel FB, Stoner GD. Inhibition of benzo[a]pyrene and benzo[a]pyrene-trans-7,8-diol metabolism and DNA binding in mouse lung explants by ellagic acid. Cancer Res 45:2951-2956 (1985).
34. Mandal S, Shivapurkar NM, Galati AJ, Stoner GD. Inhibition of N-nitrosobenzylmethylamine metabolism and DNA binding in cultured rat esophagus by ellagic acid. Carcinogenesis 9:1313-1316 (1988).
35. Barch DH, Fox CC. Dietary ellagic acid reduces the esophageal microsomal metabolism of metnylbenzylnitrosamine. Cancer Lett 44:39-44 (1989).
36. Mandai S, Stoner GD. Inhibition of N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis 11:55-61 (1990).
37. Daniel EM, Stoner GD. The effects of ellagic acid and 13-cis-retinoic acid on N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats. Cancer Lett 56:117-124 (1991).
38. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally-occurring indoles. Cancer Res 38:1410-1413 (1978).
39. 1 Carcinogenesis in rainbow trout by flavone and indole compounds. Carcinogenesis 5:615-619 (1984).
40. 1 in rainbow trout. Carcinogenesis 7:2025-2031 (1986).
41. 1. Carcinogenesis 9:427-432 (1988).
42. 1 carcinogen dose, indole-3-carbinol anti-carcinogen dose, target organ DNA adduction and final tumor response. Carcinogenesis 10:175-181 (1989).
43. Tanaka T, Mori Y, Morishita Y, Hara A, Ohno T, Kojima T, Mori H. Inhibitory effect of sinigrin and indole-3-carbinol on diethylnitrosamine-induced hepatocarcinogenesis in male ACI/N rats. Carcinogenesis 11:1403-1406 (1990).
44. Morse MA, LaGreca SD, Amin SG, Chung F-L. Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and on the metabolism and disposition of NNK in A/J mice. Cancer Res 50:2613-2617 (1990).
45. 6-methylguanine-DNA-transmethylase activity and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA methylation and tumorigenicity in F344 rats. Carcinogenesis 9:1891-1895 (1988).
46. Pence BC, Buddingh F, Yang SP. Multiple dietary factors in the enhancement of dimethylhydrazine Carcinogenesis: main effect of indole-3-carbinol. J Natl Cancer Inst 77:269-276 (1986).
47. Bailey GS, Hendricks JD, Shelton DW, Nixon JE, Pawlowski NE. Enhancement of Carcinogenesis by the natural anticarcinogen indole-3-carbinol. J Natl Cancer Inst 78:931-934 (1987).
48. Zhang Y, Talalay P, Cho C-G, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89:2399-2403 (1992).
49. Zhang Y, Kensler TW, Cho C-G, Posner GH, Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91:3147-3150 (1994).
50. Wattenberg LW, Bueding E. Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine, and uracil mustard. Carcinogenesis 7:1379-1381 (1986).
51. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiolthione. Carcinogenesis 6:759-763 (1985).
52. Kensler TW, Egner PA, Dola PM, Groopman JD, Roebuck BD. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-thones. Cancer Res 47:4271-4277 (1987).
53. 1 in the rat. Toxicol Appl Pharmacol 93:442-451 (1988).
54. Davidson NE, Egner PA, Kensler TW. Transcriptional control of glutathione S-transferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) in rat liver. Cancer Res 50:2251-2255 (1990).
55. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz): predictive role for molecular dosimetry. Cancer Res 51:5501-5506 (1991).
56. Rao CV, Tokomo K, Kelloff G, Reddy BS. Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis 12:1051-1055 (1991).
57. Wattenberg LW, Jerina DM, Lam LKT, Yagi H. Neoplastic effects of oral administration of (+/-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene and their inhibition by butylated hydroxyanisole. J Natl Cancer Inst 62:1103-1106 (1979).
58. Sato K, Kitahare A, Yin Z, Waragi F, Nishimura K, Hatayama I, Ebina T, Yamazaki T, Tsuda H, Ito N. Induction by butylated hydroxyanisole of specific molecular forms of glutathione S-transferase and UDP-glucuronyltransferase and inhibition of development of gamma-glutamyl transpeptidase-positive foci in rat liver. Carcinogenesis 5:473-477 (1984).
59. Sayer JM, Yagi H, Wood AW, Conney AH, Jerina DM. Extremely facile reaction between the ultimate carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide and ellagic acid. J Am Chem Soc 104:5562-5564 (1982).
60. Wood AW, Huang M-T, Chang RL, Newmark NL, Lehr RE, Yagi H, Sayer JM, Jerina DM, Conney AH. Inhibition of the mutagenicity of bay-region diol-epoxides of polycyclic aromatic hydrocarbons by naturally occurring plant phenols: exceptional activity of ellagic acid. Proc Natl Acad Sci USA 79:5513-5517 (1982).
61. Chang RL, Huang M-T, Wood AW, Wong C-Q, Newmark HL, Yagi H, Sayer JM, Jerina DM, Conney AH. Effect of ellagic acid and hydroxylated flavonoids on the tumorigenicity of benzo[a]pyrene and (±)-7β,8α-dihydroxy-9α, 10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on mouse skin and in the newborn mouse. Carcinogenesis 6:1127-1133 (1986).
62. De Flora S, Bennicelli C, Zannachi P, Camoirano A, Morelli A, De Flora A. In vitro effects of N-acetylcysteine on the mutagenicity of direct-acting compounds and procarcinogens. Carcinogenesis 5:505-510 (1984).
63. De Flora S, Bennicelli C, Camoirano A, Serra D, Romano M, Rossi GA, Morelli A, De Flora A. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. Carcinogenesis 5:1735-1745 (1985).
64. De Flora S, Astengo M, Serra D, Bennicelli C. Inhibition of urethan-induced lung tumors in mice by dietary N-acetylcysteine. Cancer Lett 32:235-241 (1986).
65. Frenkel K. Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol Ther 53:126-166 (1992).
66. Pryor WA. Why is the hydroxyl radical the only radical that commonly adds to DNA? Hypothesis: It has a rare combination of high electrophilicity, nigh thermochemical reactivity, and a mode of production that can occur near DNA. Free Radical Biol Med 4:219-223 (1988).
67. Foote CS, Chang YC, Denny RW. Chemistry of singlet oxygen. X: Carotenoid quenching parallels biological protection. J Am Chem Soc 92:5216-5218 (1970).
68. Packer JE, Mahood JS, Mora-Arellano VO, Slater TF, Willson RL, Wolfenden BS. Free radicals and singlet oxygen scavengers: reaction of a peroxy radical with beta-carotene, diphenyl furan and 1,4-diazobicyclo (2,2,2)-octane. Biochem Biophys Res Commun 98:901-906 (1981).
69. Kensler TW, Trush MA, Guyton KZ. Free radicals as targets for cancer chemoprevention: prospects and problems. In: Cellular and Molecular Targets for Chemoprevention (Steele VE, Stoner GD, Boone CW, Kelloff GJ, eds). Boca Raton, FL:CRC Press, 1992;173-191.
70. Kelloff GJ, Boone CW, Steele VE, Fay JR, Lubet RA, Crowell JA, Sigman CC. Mechanistic considerations in chemopreventive drug development. J Cell Biochem (Suppl)20:1-24 (1994).
71. Kelloff GJ, Boone CW, Steele VE, Ray JR, Sigman CC. Inhibition of chemical carcinogenesis. In: Chemical Induction of Cancer: Modulation and Combination Effects (Arcos J, Argus M, Woo Y, eds). Boston:Birkhauser Boston, in press.
72. Imanishi H, Sasaki YF, Matsumoto K, Watanabe M, Ohta T, Shirasu Y, Tutikawa K. Suppression of 6-TG-resistant mutations in V79 cells and recessive spot formations in mice by vanillin. Mutat Res 243:151-158 (1990).
73. Farzaneh F, Panayotou GN, Bowler LD, Hardas BD, Broom T, Walther C, Shall S. ADP-ribosylation is involved in the integration of foreign DNA into the mammalian cell genome. Nucleic Acid Res 16:1319-1326 (1988).
74. Scovassi AI, Stefanini M, Lagomarsini P, Izzo R, Bertazzoni U. Response of mammalian ADP-ribosyl transferase to lymphocyte stimulation, mutagen treatment and cell cycling. Carcinogenesis 8:1295-1300 (1987).
75. Cesarone CF, Scovassi AI, Scarabelli L, Izzo R, Orunesu M, Bertazzoni U. Depletion of adenosine diphosphate-ribosyl transferase activity in rat liver during exposure to N-2-acetylaminofluorene: effect of thiols. Cancer Res 48:3581-3585 (1988).
76. Meyn SM, Rossman T, Troll WA. A protease inhibitor blocks SOS functions in Escherichia coli: Antipain prevents lambda repressor inactivation, ultraviolet mutagenesis, and filamentous growth. Proc Natl Acad Sci USA 74:1152-1156 (1977).
77. Baturay N, Kennedy AR. Pyrene acts as a cocarcinogen with the carcinogens benzo[a]pyrene, beta-propriolactone and radiation in the induction of malignant transformation in cultured mouse fibroblasts, soybean extract containing the Bowman-Birk inhibitor acts as an anticarcinogen. Cell Biol Toxicol 2:21-32 (1986).
78. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal tumor development. N Engl J Med 319:525-532 (1988).
79. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61:759-767 (1990).
80. De Flora S, Ramel C. Classification of mechanisms of inhibitors of mutagenesis and carcinogenesis. Basic Life Sci 52:461-462 (1990).
81. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48:759-774 (1988).
82. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 53:749-790 (1984).
83. Slaga TJ. Overview of tumor promotion in animals. Environ Health Perspect 50:3-14 (1983).
84. Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.G. 4.1.1.17.) by substrate and product analogues. J Am Chem Soc 100:2551-2553 (1978).
85. Fozard JR, Prakash NJ. Effects of D,L-α-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumor induced by 7,12-dimethyl-benz[a]anthracene. Arch Pharmacol 28:1-6 (1982).
86. Weeks CE, Herrmann AL, Nelson FR, Slaga TJ. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor-promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci USA 79:6028-6032 (1982).
87. Thompson HJ, Ronan AM. Inhibition of 1-methyl-1-nitrosourea induced mammary tumorigenesis by α-difluoromethylornithine and retinyl acetate. Proc Am Assoc Cancer Res 24:86 (1983).
88. Kingsnorth AN, King WWK, Diekema KA, McCann PP, Ross JS, Malt RA. Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice. Cancer Res 43:2545-2549 (1983).
89. Takigawa M, Verma AJ, Simsiman RC, Boutwell RK, Inhibition of mouse skin tumor promotion and of promoterstimulated epidermal polyamine biosynthesis by α-difluoromethylornithine. Cancer Res 43:3732-3738 (1983).
90. Homma Y, Kakizoe T, Samma S, Oyasu R. Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by α-difluoromethylornithine. Cancer Res 47:6176-6179 (1987).
91. Reddy BS, Nayini J, Tokumo K, Rigotry J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50:2562-2568 (1990).
92. Tanaka T, Kojima T, Hara A, Sawada H, Mori H. Chemoprevention of oral carcinogenesis by D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats. Cancer Res 53:772-776 (1993).
93. Whitfield JF. Calcium: driver of cell cycles, trigger of differentiation, and killer of cells. In: Cellular and Molecular Targets for Chemoprevention (Steele VE, Stoner GD, Boone CW, Kelloff GJ, eds). Boca Raton, FL:CRC Press, 1992;257-311.
94. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. Fed Am Soc Exp Biol J 5:2924-2933 (1991).
95. Newton DL, Henderson WR, Sporn MB. Structure-activity relationships of retinoids in hamster tracheal organ culture. Cancer Res 40:3413-3425 (1980).
96. Huang FL, Roop DR, De Luca LM. Vitamin A deficiency and keratin biosynthesis in cultured hamster trachea. In Vitro Cell Dev Biol 22:223 (1986).
97. McDowell EM, Ben T, Newkirk C, Chang S, De Luca L. Differentiation of tracheal mucociliary epithelium in primary cell culture recapitulates normal fetal development and regeneration following injury in hamsters. Am J Pathol 129:511-522 (1987).
98. Bashor MM, Toft DO, Chytil F. In vitro binding of retinol to rat tissue components. Proc Natl Acad Sci USA 70:3483-3487 (1973).
99. Sani BP, Hill DL. A retinoic acid-binding protein from chick embryo skin. Cancer Res 36:409-413 (1976).
100. Sani BP, Singh RK, Reddy LG, Gaub M-P. Isolation, partial purification and characterization of nuclear retinoic acid receptors from chick skin. Arch Biochem Biophys 283:107-113 (1990).
101. Hennings H, Michael D, Cheng C, Steinert P, Holbrook K, Yuspa SH. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 19:245-254 (1980).
102. Babcock MS, Marino MS, Gunning WT III, Stoner GD. Clonal growth and serial propagation of rat esophageal epithelial cells. In Vitro 19:403-415 (1983).
103. Scalmati A, Lipkin M, Newmark H. Relationsips of calcium and vitamin D to colon cancer. In: Cancer Chemoprevention (Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds). Boca Raton, FL:CRC Press, 1992;249-262.
104. McGrath CM, Soule HD. Calcium regulation of normal human mammary epithelial cell growth in culture. In Vitro 20:652-662 (1984).
105. Soule HD, McGrath CM. A simplified method for passage and long-term growth of human mammary epithelial cells. In Vitro 22:6-12 (1986).
106. 3. Proc Natl Acad Sci USA 78:4990-4994 (1981).
107. 3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 102:937-943 (1981).
108. Osterm VK, De Luca HF. The vitamin D-induced differentiation of HL-60 cells: structural requirements. Steroids 49:73-102 (1987).
109. Goldman R. Synergism and antagonism in the effects of 1α,25-dihydroxyvitamin 03, retinoic acid, dexamethasone, and a tumor-promoting phorbol ester on the functional capacity P388D1 cells: phagocytosis and transglutaminase activity. Cancer Res 45:3118-3124 (1985).
110. Roberts AB, Sporn MB. Transforming growth factor β. Adv Cancer Res 51:107-145 (1988).
111. Silberstein GB, Daniel CW. Reversible inhibition of mammary gland growth by transforming growth factor-β. Science 237:291-293 (1987).
112. Sporn MB, Roberts AB, Glick AB, Luckert PH, Pollard M. Interactions of retinoids and transforming growth factor β in the chemoprevention of cancer. In: Control of Growth Factors and Prevention of Cancer (Sporn MB, ed). New York: Springer-Verlag, 1992;37-46.
113. Russell WE, Coffrey RJ Jr, Ouellette AJ, Moses HL. Type β transforming growth factor reversibility inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci USA 85:5126-5130 (1988).
114. Jordan VC. The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70:977-982 (1992).
115. Pollak MN, Huynh HT, Lefebvre SP. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22:91-100 (1992).
116. Macauley VM. Insulin-like growth factors and cancer. Br J Cancer 65:311-320 (1992).
117. Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN. Anti-carcinogenic activity of D-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 9:331-332 (1988).
118. Russin WA, Hoesly JD, Elson CE, Tanner MA, Gould MN. Inhibition of rat mammary carcinogenesis by monoterpenoids. Carcinogenesis 10:2161-2164 (1989).
119. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26 kDa proteins by the anticarcinogen D-limonene and its metabolites. J Biol Chem 266:17679-17685 (1991).
120. Troll W, Kennedy AR. Protease inhibitors as cancer chemopreventive agents. Cancer Res 49:499-502 (1988).
121. Klaunig J, Ruch RJ. Role of inhibition of intercellular communication in carcinogenesis. Lab Invest 62:135-146 (1990).
122. Bertram JS, Hossain MZ, Zhang L-X. Use of cell culture systems for mechanistic studies of chemopreventive agents. In: Cellular and Molecular Targets for Chemoprevention (Steele VE, Stoner GD, Boone CW, Kelloff GJ, eds). Boca Raton, FL:CRC Press, 1992;43-62.
123. Lowenstein WR. Junctional intercellular communication and the control of growth. Biochem Biophys Acta 560:1-65 (1979).
124. Mehta PP, Bertram JS, Lowenstein WR. Growth inhibition of transformed cells correlates with their junctional communication with normal cells. Cell 44:187-196 (1986).
125. Mehta PP, Bertram JS, Lowenstein WR. The actions of retinoids on cellular growth correlate with their actions on gap junctional communication. J Cell Biol 108:1053-1065 (1989).
126. Zhang L-X, Cooney RV, Bertram JS. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. Carcinogenesis 12:2109-2114 (1991).
127. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation in human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936-2940 (1980).
128. Hill DL, Grubbs CJ, Retinoids and cancer prevention. Annu Rev Nutr 12:161-181 (1992).
129. Kiremidijian-Schumacher L, Stotsky G. Selenium and immune reponses. Environ Res 42:277-303 (1987).
130. Tengerdy RP. Effect of vitamin E on immune function. In: Vitamin E - A Comprehensive Treatise (Machlin LJ, ed). New York-Marcel Dekker, 1980;429-444.
131. Corwin RM, Gordon RK. Vitamin E and immune regulation. Ann NY Acad Sci 393:437-451 (1982).
132. Schwartz J, Odukoya O, Stoufi E, Shklar G. Alpha-tocopherol alters the distribution of Langerhans cells in DMBA-treated hamster cheek pouch epithelium. J Dent Res 64:117-121 (1985).
133. Sen S, D'lncalci M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307:122-127 (1992).
134. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 13:245-251 (1992).
135. Yonish-Rouach E, Resnitsky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347 (1991).
136. Oren M. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev 11:141-148 (1992).
137. Oberhammer F, Bursch W, Parzefall W, Breit P, Erber E, Stadler M, Schulte-Hermann R. Effect of transforming growth factor β on cell death of cultured rat hepatocytes. Cancer Res 51:2478-2485 (1991).
138. Kypriamou N, Englaish HF, Isaacs JT. Programming cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3478-3753 (1990).
139. Bursch W, Liehr JG, Sirbasku DA, Putz B, Taper H, Schulte-Hermann R. Control of cell death (apoptosis) by diethylstilbesterol in an estrogen-dependent kidney tumor. Carcinogenesis 12:855-860 (1991).
140. Piazza GA, Rahm ALK, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55:3110-3116 (1995).
141. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 157:175-179 (1990).
142. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-639 (1991).
143. Wainfain E, Poirier LA. Methyl groups in carcinogenesis: effects of DNA methylation and gene expression. Cancer Res 52:2071s-2077s (1992).
144. Mikol YB, Hoover KL, Creasia D, Poirier LA. Hepatocarcinogenesis in rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis 4:1619-1629 (1983).
145. Ghoshal AK, Farber E. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens. Carcingenesis 5:1367-1370 (1984).
146. Yokoyama S, Sells MA, Reddy TV, Lombardi B. Hepatocarcinogenic and promoting action of a choline-devoid diet in the rat. Cancer Res 45:2834-2842 (1985).
147. Brada Z, Altman NH, Hill M, Bulba S. The effect of methionine on the progression of hepatocellular carcinoma induced by ethionine. Res Commun Chem Pathol Pharmacol 38:157-160 (1982).
148. Hoffman RM. Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis - a review and synthesis. Biochem Biophys Acta 738:49-87 (1984).
149. Wainfan E, Dizik M. Suppression by methionine and choline of onco-fetal patterns of liver tRNA methyltransferase activities in carcinogen treated rats. Carcinogenesis 8:615-617 (1987).
150. Dizik M, Christman JK, Wainfan E. Alterations in expression and methylation of specific genes in livers of rats fed a cancer-promoting, methyl-deficient diet. Carcinogenesis 12:1307-1312 (1991).
151. Wainfan E, Dizik M, Shiekhnejad G, Christman JK. Early changes in nucleic acid methylation and gene expression in livers of rats fed cancer-promoting, methyl-deficient diets. Fed Am Soc Exp Biol J 4:A1043 (1990).
152. Hocman G. Chemoprevention of cancer: protease inhibitors. Int J Biochem 24:1365-1375 (1992).
153. Moncada S, Flower RJ, Vane JR. Prostaglandins, prostacyclin, and thromboxane A2. In: The Pharmacological Basis of Therapeutics. 6th ed (Gilman AG, Goodman LS, Gilman A, eds). New York:McMillan, 1980;668-681.
154. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 47:5340-5346 (1987).
155. Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 71:260-264 (1980).
156. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin. Cancer Res 41:1954-1957 (1981).
157. Boone CW, Steele VE, Kelloff GJ. Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res 267:251-255 (1992).
158. Nakadate T, Yamamoto S, Aizu E, Kato R. Inhibition by lipoxygenase inhibitors of 7-bromomethylbenz[a]anthracenecaused epidermal ornithine decarboxylase induction and skin tumor promotion in mice. Carcinogenesis 10:2053-2057 (1989).
159. Huang M-T, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51:813-819 (1991).
160. Huang M-T, Smart RC, Wong C-Q, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 48:5941-5946 (1988).
161. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:795-801 (1990).
162. Garewal HS, Meyskens FL Jr, Reeves D, Kiersch TA, Elletson H, Strosberg A, King D, Steinbronn K. Response of oral leukoplakia to beta-carotene. J Clin Oncol 8:1715-1720 (1990).
163. Kelloff GJ, Johnson JJ, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomark Prev 4:1-10 (1995).
164. Brown ML. The national economic burden of cancer: an a update. J Natl Cancer Inst 23:1811-1814 (1990).